PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
0.06 - 0.06
0.06 - 0.24
8.7K / 3.59M (Avg.)
-1.55 | -0.04
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
372730.40%
10Y CAGR of 372730.40% while CRN.AX is zero. Bruce Berkowitz would see if incremental growth can widen into a significant edge.
372730.40%
5Y CAGR of 372730.40% while CRN.AX is zero. Bruce Berkowitz would see if small improvements can scale into a larger advantage.
No Data
No Data available this quarter, please select a different quarter.
100.44%
OCF/share CAGR of 100.44% while CRN.AX is zero. Bruce Berkowitz might see a slight advantage that could compound over time.
100.44%
OCF/share CAGR of 100.44% while CRN.AX is zero. Bruce Berkowitz would see if modest momentum can translate into a bigger competitive lead.
100.23%
3Y OCF/share CAGR of 100.23% while CRN.AX is zero. Bruce Berkowitz might see if small gains can expand into a broader advantage.
232.49%
10Y net income/share CAGR of 232.49% while CRN.AX is zero. Bruce Berkowitz would see if minor gains can compound into a bigger lead over time.
232.49%
Net income/share CAGR of 232.49% while CRN.AX is zero. Bruce Berkowitz would see if small mid-term gains can develop into a bigger lead.
123.38%
3Y net income/share CAGR of 123.38% while CRN.AX is zero. Bruce Berkowitz sees if minor improvements can widen to a bigger advantage.
-97.02%
Negative equity/share CAGR over 10 years while CRN.AX stands at 0.00%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-97.02%
Negative 5Y equity/share growth while CRN.AX is at 0.00%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-87.36%
Negative 3Y equity/share growth while CRN.AX is at 0.00%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.